Hepatitis B virus and human T-cell lymphotropic virus type 1 co-infection in the Northern Territory, Australia

Ian Marr, Jane Davies, Rob W. Baird

    Research output: Contribution to journalArticleResearchpeer-review

    9 Downloads (Pure)

    Abstract

    Objective: To establish the relationship between hepatitis B virus (HBV) and human T-cell lymphotropic virus type 1 (HTLV-1) serological markers in the Northern Territory, Australia. 

    Methods: A retrospective serological study of patients presenting to public healthcare facilities in the Northern Territory between 2008 and 2015 was performed in order to determine the presence and relationships of serological markers of HBV and HTLV-1. 

    Results: Seven hundred and forty individual patients were found to be serologically positive for HTLV-1 in the Northern Territory over the 8-year period. Hepatitis B results were available for 521 of these patients. Hepatitis B surface antigen (HBsAg) positivity was demonstrated in 15.9% (83/521) of this cohort, which was significantly different to the HTLV-1-negative group (3.7%, 125/3354) (p < 0.001). Excluding individuals with isolated hepatitis B surface antibody (anti-HBs), those in the HTLV-1-positive group had a higher HBV exposure history (67.5%, 352/521) when compared to HTLV-1-negative individuals (37.8%, 1259/3354) (p < 0.001). HTLV-1-positive individuals had a lower prevalence of HBV combined anti-HBs and hepatitis B core antibody (anti-HBc) positive markers compared to those who were HTLV-1-negative (56.3% (198/352) versus 73.8% (937/1269), respectively; p < 0.001). 

    Conclusions: A significantly higher prevalence rate of HBV was found in HTLV-1-positive individuals from the Northern Territory. When considering the higher exposure to HBV in HTLV-1-positive individuals, the clearance of HBV appears lower than in those individuals testing HTLV-1-negative. A lower prevalence of clearance in HTVL-1-positive individuals than in HTLV-1-negative individuals, as signified by formation of HBVcAb and HBVsAb in HTVL-1 positive individual's may equate to higher prevalence of ongoing coinfection.

    Original languageEnglish
    Pages (from-to)90-95
    Number of pages6
    JournalInternational Journal of Infectious Diseases
    Volume58
    DOIs
    Publication statusPublished - May 2017

    Fingerprint

    Northern Territory
    Human T-lymphotropic virus 1
    Coinfection
    Hepatitis B virus
    T-Lymphocytes
    Hepatitis B Antibodies
    Public Facilities
    Hepatitis B Surface Antigens
    Hepatitis B

    Cite this

    @article{9155fcb4abcc4be5adb0808606e2027b,
    title = "Hepatitis B virus and human T-cell lymphotropic virus type 1 co-infection in the Northern Territory, Australia",
    abstract = "Objective: To establish the relationship between hepatitis B virus (HBV) and human T-cell lymphotropic virus type 1 (HTLV-1) serological markers in the Northern Territory, Australia. Methods: A retrospective serological study of patients presenting to public healthcare facilities in the Northern Territory between 2008 and 2015 was performed in order to determine the presence and relationships of serological markers of HBV and HTLV-1. Results: Seven hundred and forty individual patients were found to be serologically positive for HTLV-1 in the Northern Territory over the 8-year period. Hepatitis B results were available for 521 of these patients. Hepatitis B surface antigen (HBsAg) positivity was demonstrated in 15.9{\%} (83/521) of this cohort, which was significantly different to the HTLV-1-negative group (3.7{\%}, 125/3354) (p < 0.001). Excluding individuals with isolated hepatitis B surface antibody (anti-HBs), those in the HTLV-1-positive group had a higher HBV exposure history (67.5{\%}, 352/521) when compared to HTLV-1-negative individuals (37.8{\%}, 1259/3354) (p < 0.001). HTLV-1-positive individuals had a lower prevalence of HBV combined anti-HBs and hepatitis B core antibody (anti-HBc) positive markers compared to those who were HTLV-1-negative (56.3{\%} (198/352) versus 73.8{\%} (937/1269), respectively; p < 0.001). Conclusions: A significantly higher prevalence rate of HBV was found in HTLV-1-positive individuals from the Northern Territory. When considering the higher exposure to HBV in HTLV-1-positive individuals, the clearance of HBV appears lower than in those individuals testing HTLV-1-negative. A lower prevalence of clearance in HTVL-1-positive individuals than in HTLV-1-negative individuals, as signified by formation of HBVcAb and HBVsAb in HTVL-1 positive individual's may equate to higher prevalence of ongoing coinfection.",
    keywords = "Australia, Co-infection, Hepatitis B virus, HTLV-1, Northern Territory",
    author = "Ian Marr and Jane Davies and Baird, {Rob W.}",
    year = "2017",
    month = "5",
    doi = "10.1016/j.ijid.2017.03.010",
    language = "English",
    volume = "58",
    pages = "90--95",
    journal = "International Journal of Infectious Diseases",
    issn = "1201-9712",
    publisher = "BC Decker",

    }

    Hepatitis B virus and human T-cell lymphotropic virus type 1 co-infection in the Northern Territory, Australia. / Marr, Ian; Davies, Jane; Baird, Rob W.

    In: International Journal of Infectious Diseases, Vol. 58, 05.2017, p. 90-95.

    Research output: Contribution to journalArticleResearchpeer-review

    TY - JOUR

    T1 - Hepatitis B virus and human T-cell lymphotropic virus type 1 co-infection in the Northern Territory, Australia

    AU - Marr, Ian

    AU - Davies, Jane

    AU - Baird, Rob W.

    PY - 2017/5

    Y1 - 2017/5

    N2 - Objective: To establish the relationship between hepatitis B virus (HBV) and human T-cell lymphotropic virus type 1 (HTLV-1) serological markers in the Northern Territory, Australia. Methods: A retrospective serological study of patients presenting to public healthcare facilities in the Northern Territory between 2008 and 2015 was performed in order to determine the presence and relationships of serological markers of HBV and HTLV-1. Results: Seven hundred and forty individual patients were found to be serologically positive for HTLV-1 in the Northern Territory over the 8-year period. Hepatitis B results were available for 521 of these patients. Hepatitis B surface antigen (HBsAg) positivity was demonstrated in 15.9% (83/521) of this cohort, which was significantly different to the HTLV-1-negative group (3.7%, 125/3354) (p < 0.001). Excluding individuals with isolated hepatitis B surface antibody (anti-HBs), those in the HTLV-1-positive group had a higher HBV exposure history (67.5%, 352/521) when compared to HTLV-1-negative individuals (37.8%, 1259/3354) (p < 0.001). HTLV-1-positive individuals had a lower prevalence of HBV combined anti-HBs and hepatitis B core antibody (anti-HBc) positive markers compared to those who were HTLV-1-negative (56.3% (198/352) versus 73.8% (937/1269), respectively; p < 0.001). Conclusions: A significantly higher prevalence rate of HBV was found in HTLV-1-positive individuals from the Northern Territory. When considering the higher exposure to HBV in HTLV-1-positive individuals, the clearance of HBV appears lower than in those individuals testing HTLV-1-negative. A lower prevalence of clearance in HTVL-1-positive individuals than in HTLV-1-negative individuals, as signified by formation of HBVcAb and HBVsAb in HTVL-1 positive individual's may equate to higher prevalence of ongoing coinfection.

    AB - Objective: To establish the relationship between hepatitis B virus (HBV) and human T-cell lymphotropic virus type 1 (HTLV-1) serological markers in the Northern Territory, Australia. Methods: A retrospective serological study of patients presenting to public healthcare facilities in the Northern Territory between 2008 and 2015 was performed in order to determine the presence and relationships of serological markers of HBV and HTLV-1. Results: Seven hundred and forty individual patients were found to be serologically positive for HTLV-1 in the Northern Territory over the 8-year period. Hepatitis B results were available for 521 of these patients. Hepatitis B surface antigen (HBsAg) positivity was demonstrated in 15.9% (83/521) of this cohort, which was significantly different to the HTLV-1-negative group (3.7%, 125/3354) (p < 0.001). Excluding individuals with isolated hepatitis B surface antibody (anti-HBs), those in the HTLV-1-positive group had a higher HBV exposure history (67.5%, 352/521) when compared to HTLV-1-negative individuals (37.8%, 1259/3354) (p < 0.001). HTLV-1-positive individuals had a lower prevalence of HBV combined anti-HBs and hepatitis B core antibody (anti-HBc) positive markers compared to those who were HTLV-1-negative (56.3% (198/352) versus 73.8% (937/1269), respectively; p < 0.001). Conclusions: A significantly higher prevalence rate of HBV was found in HTLV-1-positive individuals from the Northern Territory. When considering the higher exposure to HBV in HTLV-1-positive individuals, the clearance of HBV appears lower than in those individuals testing HTLV-1-negative. A lower prevalence of clearance in HTVL-1-positive individuals than in HTLV-1-negative individuals, as signified by formation of HBVcAb and HBVsAb in HTVL-1 positive individual's may equate to higher prevalence of ongoing coinfection.

    KW - Australia

    KW - Co-infection

    KW - Hepatitis B virus

    KW - HTLV-1

    KW - Northern Territory

    UR - http://www.scopus.com/inward/record.url?scp=85017405702&partnerID=8YFLogxK

    U2 - 10.1016/j.ijid.2017.03.010

    DO - 10.1016/j.ijid.2017.03.010

    M3 - Article

    VL - 58

    SP - 90

    EP - 95

    JO - International Journal of Infectious Diseases

    JF - International Journal of Infectious Diseases

    SN - 1201-9712

    ER -